ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020
Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Degenerative Cervical Myelopathy Diagnosis and Its Differentiation from Neurological Mimics, MS and ALS: A Literature Review.Journal of clinical medicine · 2025Review
- Health Care Use Before Multiple Sclerosis Symptom Onset.JAMA network open · 2025Article
- The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis.Neurology and therapy · 2025Review
- Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.Neurology · 2025Article
- Central Vein Sign and Paramagnetic Rim Lesions: Susceptibility Changes in Brain Tissues and Their Implications for the Study of Multiple Sclerosis Pathology.Diagnostics (Basel, Switzerland) · 2024Review
- A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.AJR. American journal of roentgenology · 2023Article
- Neurodegeneration in multiple sclerosis.WIREs mechanisms of disease · 2023Review
- Central vein sign: comparison of multiple sclerosis and leukoaraiosis.Turkish journal of medical sciences · 2022Article
- Smoldering lesions in MS: if you like it then you should put a rim on it.Neuroradiology · 2022Article
- Sensitivity and Specificity of Central Vein Sign as a Diagnostic Biomarker in Egyptian Patients with Multiple Sclerosis.Neuropsychiatric disease and treatment · 2022Article
- The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis.Diagnostics (Basel, Switzerland) · 2020Review
- Iron Rims as an Imaging Biomarker in MS: A Systematic Mapping Review.Diagnostics (Basel, Switzerland) · 2020Review
- Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis.AJNR. American journal of neuroradiology · 2020Article
- Dawson's Fingers in Cerebral Small Vessel Disease.Frontiers in neurology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMisdiagnosis is common in multiple sclerosis (MS) as a proportion of patients present with atypical clinical/magnetic resonance imaging (MRI) findings. The central vein sign has the potential to be a non-invasive, MS-specific biomarker.
objectiveTo test the accuracy of the central vein sign in predicting a diagnosis of MS in patients with diagnostic uncertainty at disease presentation using T2*-weighted, 3 T MRI.
methodsIn this prospective pilot study, we recruited individuals with symptoms unusual for MS but with brain MRI consistent with the disease, and those with a typical clinical presentation of MS whose MRI did not suggest MS. We calculated the proportion of lesions with central veins for each patient and compared the results to the eventual clinical diagnoses. The optimal central vein threshold for diagnosis was established.
resultsThirty-eight patients were scanned, 35 of whom have received a clinical diagnosis. Median percentage of lesions with central veins was 51% in MS and 28% in non-MS. A threshold of 40.7% lesions with central veins resulted in 100% sensitivity and 73.9% specificity.
conclusionThe central vein sign assessed with a clinically available T2* scan can successfully diagnose MS in cases of diagnostic uncertainty. The central vein sign should be considered as a diagnostic biomarker in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.